Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Are the Key Projections for the CAGR of the Diabetic Macular Edema (DME) Market Size From 2025 to 2034?
The market size of diabetic macular edema (dme) has experienced a steady increase in the last few years. It is projected to elevate from $4.67 billion in 2024 to $4.88 billion in 2025, marking a compound annual growth rate (CAGR) of 4.4%. This escalation during the historic period is a result of factors such as the rising frequency of diabetes, elevated incidences of disorders related to edema, increased instances of diabetic eye ailments, a surge in the population of elderly people, and the growing number of blindness cases.
In the coming years, the market for diabetic macular edema (dme) is projected to experience consistent growth, expected to reach the value of$5.77 billion in 2029 with a compound annual growth rate (CAGR) of 4.3%. A combination of factors such as increasing healthcare access, heightened government backing in healthcare, more awareness about diabetes-related complications, the rise in use of telemedicine for eye care, and growth in specialized centers for diabetic eye care contribute to this forward trend. Key market trends during the forecast period would be the development of therapies targeting anti-VEGF, the utilization of corticosteroid implants, breakthroughs in drug delivery systems, innovation in retinal laser therapy, AI-driven diagnostic tools, and the acceptance of less invasive surgical procedures.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21169&type=smp
Which Factors and External Forces Are Driving Demand in the Diabetic Macular Edema (DME) Market?
The rise in diabetes cases is anticipated to propel the progression of the diabetic macular edema (DME) market in the future. The escalating incidence of diabetes is due to aspects like inactive lifestyles, poor food habits, increasing obesity, aging societies, and genetic susceptibility. Diabetes engenders diabetic macular edema through harm to retinal blood vessels, initiating fluid seepage into the macula, leading to swelling. For example, in June 2023, the Institute for Health Metrics and Evaluation, a US-based public health research institute, revealed that over 500 million people worldwide were dealing with diabetes. This figure is predicted to more than double, amounting to 1.3 billion people by 2050. Thus, the escalating occurrence of diabetes is fuelling the expansion of the diabetic macular edema (DME) market.
Which Segments in the Diabetic Macular Edema (DME) Offer the Most Growth?
The diabetic macular edema (dme)market covered in this report is segmented –
1) By Treatment: Anti-VEGF Therapy; Corticosteroids; Laser Therapy; Surgical Intervention
2) By Disease Stage: Early Stage; Moderate Stage; Advanced Stage
3) By Patient Demographics: Adults; Elderly; Children
4) By Route Of Administration: Intravitreal Injection; Topical; Systemic
5) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
Subsegments:
1) By Anti-VEGF Therapy: Monoclonal Antibodies; Recombinant Protein-Based Therapies
2) By Corticosteroids: Intravitreal Steroid Injections; Injectable Sustained-Release Corticosteroids
3) By Laser Therapy: Focal Laser Photocoagulation; Panretinal Photocoagulation
4) By Surgical Intervention: Vitrectomy; Membrane Peeling
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=21169&type=smp
What Are the Fastest-Growing Geographies in the #Which Factors and External Forces Are Driving Demand in the Diabetic Macular Edema (DME) Market?# Market?
North America was the largest region in the diabetic macular edema (DME) market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the diabetic macular edema (DME) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Which Cutting-Edge Market Trends Are Expected to Drive theDiabetic Macular Edema (DME) Market’s Growth?
Leading corporations in the diabetic macular edema (DME) treatment market are centering their efforts on technological advances such as sophisticated drug treatment methods to enhance patient management and treatment results. Innovative drug therapies employ the latest technology and research to optimise treatment of intricate health issues. Aiming to increase effectiveness, decrease adverse effects, and assure enhanced patient outcomes, they herald a new era in healthcare. A case in point is the approval by the European Commission in March 2022 for the use of Beovu, a product of the Switzerland-based pharmaceutical firm, Novartis AG, for managing visual issues arising from DME. The green light was given after Phase III KESTREL and KITE studies showed that Beovu was as effective as aflibercept in improving vision after the first year. It is worth noting that more than half of the patients treated with Beovu adhered to a 12-week treatment plan and experienced less retinal fluid than those treated with aflibercept.
View the full report here:
https://www.thebusinessresearchcompany.com/report/diabetic-macular-edema-dme-global-market-report
What Are the Key Elements That Define the Diabetic Macular Edema (DME) Market?
Diabetic macular edema (DME) is a complication of diabetes that occurs when fluid accumulates in the macula, the central part of the retina responsible for sharp vision. This swelling is caused by damaged blood vessels leaking fluid and proteins into the retinal tissue, leading to vision impairment or blindness if left untreated. DME is a common cause of vision loss in diabetic patients and is associated with diabetic retinopathy.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21169
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model